Syngeneic models involve implantation of available mouse tumor cell lines into immunocompetent mice of the same genetic background to conduct in vivo efficacy evaluation of potential cancer immunotherapy.
Case： Validation of EMT6 tumorigenic capacity in BALB/c mice
EMT6 is a murine mammary carcinoma cell line derived from a transplanted hyperplastic alveolar nodule of a BALB/c mouse.
Fig1. Analysis of Tumorigenesis in Balb/c mice(n=4). a Tumor volume was measured by time. EMT6 cells were inoculated in the fat pads of Balb/c mice. b Body weight was simultaneously checked.
Fig2. Analysis of Tumorigenesis in Balb/c mice（n=5）. a Tumor volume was measured by time. EMT6 cells were subcutaneously inoculated in Balb/c mice. b Body weight was simultaneously checked.
Available syngeneic cell lines
Available Humanized Drug Target mouse strains
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.Learn more
After the base is put into operation, SMOC’s capability to provide genetically modified rat/mouse models and technical services including gene function research and drug development will be greatly enhanced.Learn more